Last Updated on November 8, 2022 by GlobeNewsWire
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) — Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences.
Guggenheim’s 4th Annual Immunology and Neurology ConferenceFireside Chat Date: November 15, 2022Fireside Chat Time: 10:10 a.m. ETLocation: St. Regis Hotel, New York, NY
Stifel 2022 Healthcare ConferenceFireside Chat date: Wednesday, November 16, 2022Fireside Chat time: 1:50 p.m. ETLocation: Lotte New York Palace Hotel, New York, NY
A live webcast of the fireside chat presentations will be available on the Investors section of the Eliem Therapeutics website at https://www.eliemtx.com. An archived replay of each of the events will remain available on Eliem’s website for at least 30 days after the event.
About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
InvestorsChris Brinzey ICR Westwickechris.email@example.com
MediaMarites CoulterVerge ScientificMcoulter@vergescientific.com415.819.2214